Target type: biologicalprocess
Any process that decreases the rate, frequency, or extent of inclusion body assembly. Inclusion body assembly is the aggregation, arrangement and bonding together of a set of components to form an inclusion body. [GOC:BHF, GOC:dph, GOC:tb]
Negative regulation of inclusion body assembly is a critical process in protein production, particularly in prokaryotic systems like bacteria. Inclusion bodies are aggregates of misfolded proteins that can form within cells, often during the overexpression of recombinant proteins. These aggregates are typically inactive and can hinder the production of functional proteins.
To prevent the formation of inclusion bodies and promote the production of correctly folded and functional proteins, various mechanisms of negative regulation are employed by cells. These mechanisms can be broadly categorized into two main approaches:
1. **Optimization of Protein Folding:** This involves manipulating the cellular environment to enhance the folding of proteins into their native, functional conformations. This can be achieved through various strategies:
* **Chaperone Expression:** Increasing the expression of chaperone proteins, such as GroEL/ES and DnaK/DnaJ, can assist in proper protein folding and prevent misfolding.
* **Reducing Expression Levels:** Lowering the expression levels of the recombinant protein can reduce the burden on the cellular machinery, allowing for more efficient folding and preventing aggregation.
* **Optimizing Growth Conditions:** Factors like temperature, pH, and nutrient availability can influence protein folding. Optimizing these conditions can enhance protein folding and reduce inclusion body formation.
2. **Preventing Aggregation:** This approach focuses on preventing the initial aggregation of misfolded proteins. Strategies include:
* **Fusion Tags:** Attaching soluble fusion tags to the recombinant protein can improve its solubility and reduce aggregation.
* **Co-expression of Folding Partners:** Co-expressing proteins that interact with the target protein can enhance folding and prevent aggregation.
* **Modification of Protein Sequence:** Modifying the amino acid sequence of the protein, such as introducing mutations that enhance solubility or reduce aggregation propensity, can be effective.
Overall, negative regulation of inclusion body assembly is a complex process that requires a multi-faceted approach. By optimizing protein folding, preventing aggregation, and controlling the cellular environment, the production of correctly folded and functional proteins can be maximized.
'"
Protein | Definition | Taxonomy |
---|---|---|
Heat shock factor protein 1 | A heat shock factor protein 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q00613] | Homo sapiens (human) |
Heat shock-related 70 kDa protein 2 | A heat shock-related 70 kDa protein 2 that is encoded in the genome of human. [PRO:DAN] | Homo sapiens (human) |
Heat shock 70 kDa protein 1A | A heat shock 70 kDa protein 1A that is encoded in the genome of human. [PRO:DAN, UniProtKB:P0DMV8] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
zm 336372 | N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide: an inhibitor of c-Raf; activates Raf-1; structure in first source | benzamides | |
adenosine diphosphate | Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position. | adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate | fundamental metabolite; human metabolite |
adenosine | quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit | adenosines; purines D-ribonucleoside | analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent |
8-aminoadenosine | |||
celastrol | monocarboxylic acid; pentacyclic triterpenoid | anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite | |
5'-(sulfonylbenzoyl)adenosine | 5'-(sulfonylbenzoyl)adenosine: covalently binds to platelet membrane | ||
quercetin | 7-hydroxyflavonol; pentahydroxyflavone | antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger | |
chir-265 | aromatic ether | ||
az-628 | AZ-628: a multikinase inhibitor; structure in first source | benzamides | |
GDC-0879 | indanes; ketoxime; primary alcohol; pyrazoles; pyridines | antineoplastic agent; B-Raf inhibitor | |
ver 155008 | VER 155008: structure in first source | purine nucleoside | |
plx4032 | aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide | antineoplastic agent; B-Raf inhibitor | |
dabrafenib | 1,3-thiazoles; aminopyrimidine; organofluorine compound; sulfonamide | anticoronaviral agent; antineoplastic agent; B-Raf inhibitor | |
tak-632 | TAK-632 : A member of the class of benzothiazoles that is 1,3-benzothiazole substituted by (cyclopropanecarbonyl)amino, 4-fluoro-3-{2-[3-(trifluoromethyl)phenyl]acetamido}phenoxy, and cyano groups at positions 2, 6 and 7, respectively. It is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAF(V600E), BRAF(WT), respectively. | (trifluoromethyl)benzenes; aromatic ether; benzothiazoles; cyclopropylcarboxamide; monofluorobenzenes; nitrile; secondary carboxamide | antineoplastic agent; apoptosis inducer; B-Raf inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; necroptosis inhibitor |
dinaciclib | pyrazolopyrimidine | ||
n2-(1h-indazole-5-yl)-n6-methyl-3-nitropyridine-2,6-diamine | KRIBB11 : A member of the class of indazoles that is 1H-indazole substituted by a [6-(methylamino)-3-nitropyridin-2-yl]amino group at position 5. It is an inhibitor of heat shock factor 1 (IC50 = 1.2muM) and suppresses tumour growth in mouse xenograft models. N2-(1H-indazole-5-yl)-N6-methyl-3-nitropyridine-2,6-diamine: a heat shock factor 1 antagonist; structure in first source |